Advertisement

Lung

pp 1–5 | Cite as

Free Desmosine is a Sensitive Marker of Smoke-Induced Emphysema

  • Jerome Cantor
  • Arnulfo Ochoa
  • Shuren Ma
  • Xingjian Liu
  • Gerard Turino
COPD

Abstract

Purpose

While the elastin-specific crosslinks, desmosine and isodesmosine (DID), are increased in blood, urine, and sputum of patients with clinically documented pulmonary emphysema, the usefulness of DID in detecting early lung injury remains untested. To this end, our laboratory has measured DID in a hamster model of smoke-induced emphysema, involving only minimal alveolar wall damage.

Methods

Animals were either treated with cigarette smoke for 2 h/day, 5 days/week, or exposed only to room air (controls) for a period of 3 months. DID levels in bronchoalveolar lavage fluid (BALF) and whole lungs were determined at monthly intervals, using liquid chromatography and tandem mass spectrometry. Lung surface area was also determined, as a measure of airspace enlargement.

Results

The portion of BALF DID not bound to peptides (free DID) was significantly higher in smoke-exposed animals at 2 months (9.2 vs 4.4 pg/mg protein; p < 0.05), whereas total BALF DID showed no significant increases over the course of the study, and total lung DID remained unchanged. There was a mild, but significant, loss of lung surface area in the smoke-exposed group at 2 months (28.8% vs 25.2%, p < 0.05), which showed no further progression, consistent with the return of free DID to control levels at 3 months.

Conclusions

These findings support the hypothesis that free DID are sensitive indicators of smoke-induced lung injury. Measurement of free DID in smokers with minimally decreased lung mass may help determine the utility of this parameter as a test for incipient pulmonary emphysema.

Keywords

Desmosine Elastin Emphysema COPD Lung 

Notes

Compliance with Ethical Standards

Conflict of interest

Jerome Cantor, Gerard Turino, and Shuren Ma are listed as inventors on USPTO patents related to the use of DID as a biomarker for COPD. None of the other authors have a conflict of interest.

Ethical Approval

All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.

References

  1. 1.
    Hogg JC, Timens W (2009) The pathology of chronic obstructive pulmonary disease. Annu Rev Pathol 4:435–459CrossRefPubMedGoogle Scholar
  2. 2.
    Tuder RM, Petrache I (2012) Pathogenesis of chronic obstructive pulmonary disease. J Clin Invest 122:2749–2755CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Shifren A, Mecham RP (2006) The stumbling block in lung repair of emphysema: elastic fiber assembly. Proc Am Thorac Soc 3:428–433CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Li B, Daggett V (2002) Molecular basis for the extensibility of elastin. J Muscle Res Cell Motil 23:561–573CrossRefPubMedGoogle Scholar
  5. 5.
    Kielty CM, Sherratt MJ, Shuttleworth CA (2002) Elastic fibres. J Cell Sci 115:2817–2828PubMedGoogle Scholar
  6. 6.
    Iadarola P, Luisetti M (2013) The role of desmosines as biomarkers for chronic obstructive pulmonary disease. Expert Rev Respir Med 7:137–144CrossRefPubMedGoogle Scholar
  7. 7.
    Turino GM, Ma S, Lin YY, Cantor JO, Luisetti M (2011) Matrix elastin: a promising biomarker for chronic obstructive pulmonary disease. Am J Respir Crit Care Med 184:637–641CrossRefPubMedGoogle Scholar
  8. 8.
    Turino GM, Lin YY, He J, Cantor JO, Ma S (2012) Elastin degradation: an effective biomarker in COPD. COPD 9:435–438CrossRefPubMedGoogle Scholar
  9. 9.
    Lindberg CA, Engstrom G, de Verdier MG, Nihlén U, Anderson M, Forsman-Semb K, Svartengren M (2012) Total desmosines in plasma and urine correlate with lung function. Eur Respir J 39:839–845CrossRefPubMedGoogle Scholar
  10. 10.
    Ma S, Turino GM, Lin YY (2011) Quantitation of desmosine and isodesmosine in urine, plasma, and sputum by LC-MS/MS as biomarkers for elastin degradation. J Chromatogr B 879:1893–1898CrossRefGoogle Scholar
  11. 11.
    Fregonese L, Ferrari F, Fumagalli M, Luisetti M, Stolk J, Iadarola P (2011) Long-term variability of desmosine/isodesmosine as biomarker in alpha-1-antitrypsin deficiency-related COPD. COPD 8:329–333CrossRefPubMedGoogle Scholar
  12. 12.
    Luisetti M, Ma S, Iadarola P, Stone PJ, Viglio S, Casado B, Lin YY, Snider GL, Turino GM (2008) Desmosine as a biomarker of elastin degradation in COPD: current status and future directions. Eur Respir J 32:1146–1157CrossRefPubMedGoogle Scholar
  13. 13.
    Ma S, Lin YY, Turino GM (2007) Measurements of desmosine and isodesmosine by mass spectrometry in COPD. Chest 131:1363–1371CrossRefPubMedGoogle Scholar
  14. 14.
    Ma S, Lin YY, Cantor JO, Chapman KR, Sandhaus RA, Fries M, Edelman JM, McElvaney MG, Turino GM (2017) The effect of alpha-1 proteinase inhibitor on biomarkers of elastin degradation in alpha-1 antitrypsin deficiency: an analysis of the rapid/rapid extension trials. J Chronic Obstr Pulm Dis 4:34–44Google Scholar
  15. 15.
    Liu X, Ma S, Liu S, Liu M, Turino G, Cantor J (2015) The ratio of free to bound desmosine and isodesmosine may reflect emphysematous changes in COPD. Lung 193:329–334CrossRefPubMedGoogle Scholar
  16. 16.
    Slowik N, Ma S, He J, Lin YY, Soldin OP, Robbins RA, Turino GM (2011) The effect of secondhand smoke exposure on markers of elastin degradation. Chest 140:946–953CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Winkler T, Suki B (2011) Emergent structure-function relations in emphysema and asthma. Crit Rev Biomed Eng 39:263–280CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Rucker RB, Dubick MA (1984) Elastin metabolism and chemistry: potential roles in lung development and structure. Environ Health Perspect 55:179–191CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Starcher BC (1986) Elastin and the lung. Thorax 41:577–585CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Osman M, Cantor JO, Roffman S, Keller S, Turino GM, Mandl I (1985) Cigarette smoke impairs elastin resynthesis in lungs of hamsters with elastase-induced emphysema. Am Rev Respir Dis 132:640–643PubMedGoogle Scholar
  21. 21.
    Cantor JO, Ma S, Turino GM (2013) What percolation theory can tell us about COPD. Med Hypotheses 81:152–155CrossRefPubMedGoogle Scholar
  22. 22.
    Anwar RA, Gerber GE, Baig KH (1977) Studies on cross-linked regions of elastin. In: Friedman M (ed) Protein crosslinking. Advances in experimental medicine and biology, vol 86. Springer, Boston, pp 709–727CrossRefGoogle Scholar
  23. 23.
    Doyle TJ, Pinto-Plata V, Morse D, Celli BR, Rosas IO (2012) The expanding role of biomarkers in the assessment of smoking-related parenchymal lung diseases. Chest 142:1027–1034CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Rosenberg SR, Kalhan R (2012) Biomarkers in chronic obstructive pulmonary disease. Transl Res 159:228–237CrossRefPubMedGoogle Scholar
  25. 25.
    Bates JH, Davis GS, Majumdar A, Butnor KJ, Suki B (2007) Linking parenchymal disease progression to changes in lung mechanical function by percolation. Am J Respir Crit Care Med 176:617–623CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Suki B, Bates JH (2011) Lung tissue mechanics as an emergent phenomenon. J Appl Physiol 110:1111–1118CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.St John’s UniversityQueensUSA
  2. 2.Mount Sinai-St Luke’s Hospital CenterNew YorkUSA
  3. 3.School of Pharmacy and Allied Health SciencesSt John’s UniversityQueensUSA

Personalised recommendations